UPDATE 1-Celgene seeks to stop Natco's generic Revlimid
CHICAGO, Sept 3
CHICAGO, Sept 3 (Reuters) - Celgene Corp (CELG.O) said it plans to file a complaint alleging infringement against India's Natco Pharma Ltd (NATP.BO), which has submitted a request to the U.S. Food and Drug Administration for authorization to make and sell generic versions of Celgene's cancer drug Revlimid in the United States.
Celgene said it intends to vigorously enforce its intellectual property rights for Revlimid, its most important drug, and will file the complaint within the required 45-day response period.
Natco's Abbreviated New Drug Application submitted to the FDA requests authorization to make the drug in 5, 10, 15, and 25 milligram capsules.
Revlimid is currently protected by 12 issued patents listed in the FDAs Approved Drug Products List and has additional patent applications pending, Celgene said. (Reporting by Debra Sherman, editing by Gerald E. McCormick)
- Police seek motive in fatal Washington state school shooting
- U.S. nurse quarantined over Ebola criticizes her treatment |
- Two deputies killed, two others hurt in California shooting spree
- Wall St. finally turning on Amazon as Bezos magic fades
- U.S., allies stage 22 air strikes in Iraq: U.S. Central Command